It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Exploring the Lifelines of the Brain: Autophagy and Lysosomal function at the Heart of Neurodegeneration
The human brain, a marvel of complexity and sophistication, is the epicenter of our consciousness, cognition, and overall well-being. It is an organ that never truly rests, continuously processing and orchestrating a symphony of activities. However, this extraordinary organ is not immune to the ravages of time and disease. Neurodegenerative diseases, a group of disorders characterized by the progressive degeneration of neurons, pose a significant challenge to human health and quality of life. Understanding the cellular mechanisms behind these disorders is vital for developing effective treatments and interventions.
Two cellular processes, autophagy and lysosomal function, have emerged as critical players in the pathophysiology of neurodegenerative diseases. Autophagy serves as the primary pathway for the selective elimination of unwanted cellular materials to maintain cellular equilibrium. This includes neurotoxic proteins such as beta-amyloid and Tau, associated with Alzheimer’s disease, alpha-synuclein related to Parkinson’s disease, and impaired organelles like mitochondria. The lysosome, often called the “stomach” of the cell, is essential in degrading and recycling cellular waste. It contains a mixture of enzymes capable of breaking down various biological molecules, including proteins, lipids, and carbohydrates. Autophagy and lysosomal function are closely intertwined, with autophagic cargo delivered to lysosomes for degradation.
Autophagy: The Cellular Cleanup Crew
The word autophagy means “self-eating,” and this is precisely what the process entails since it serves as a cellular “cleanup crew” removing damaged organelles, protein aggregates, and other cellular waste. Like all cells, neurons rely on autophagy to maintain their health and functionality. Dysregulated autophagy can lead to neuronal damage and death.
In neurodegenerative diseases, autophagy is crucial for clearing misfolded and aggregated proteins and is involved in regulating oxidative stress and mitochondrial health. Mitochondria, the cell’s energy powerhouses, are especially critical in neurons which have high energy demands. Autophagy selectively removes damaged mitochondria through a process known as mitophagy, ensuring that only healthy mitochondria continue to produce energy. Dysfunctional mitochondria are a source of oxidative stress and a common feature of neurodegenerative diseases.
The role of autophagy is further emphasized in Parkinson’s disease, where mutations in genes like PARK2 are associated with damaged mitochondria and alpha-synuclein accumulation. Dysregulated autophagy can also lead to neuroinflammation, a feature of several neurodegenerative diseases.
Lysosomal Function: The Cellular Digestive System
Lysosomes are crucial to the degrading and recycling components of the cell and in receiving autophagic cargo for degradation. When proteins and organelles earmarked for degradation come into close contact with lysosomal enzymes, they are broken down into their basic components such as amino acids, fatty acids and sugars. The cell then recycles these components to meet its energy and building block needs.
Once lysosomal function falters, the cell becomes cluttered with undigested material. This accumulation is a hallmark of lysosomal storage disorders, a group of inherited diseases resulting from mutations in lysosomal genes. In diseases like Niemann-Pick disease, lysosomal dysfunction leads to the accumulation of lipids, including neurons. Moreover such accumulation can disrupt other cellular processes, ultimately causing neurodegeneration. Although lysosomal storage disorders are not classified as neurodegenerative diseases, understanding lysosomal function is essential because these disorders often present with neurological symptoms.
The Interplay of Autophagy and Lysosomal Function
Autophagy and lysosomal function are intimately interconnected. This partnership is essential for maintaining cellular health, and its breakdown can have disastrous consequences. When the autophagic-lysosomal pathway is compromised, it creates a vicious cycle. Autophagy cannot efficiently clear aggregated proteins or damaged organelles, and lysosomes become overwhelmed with undigested material. This leads to cellular stress and inflammation, further compromising cellular function and contributing to neuronal death.
The first step of autophagy and content degradation is the formation of autophagosomes (Figure 1). Autophagosomes are double-membraned structures that encapsulate cellular components to be degraded. Damaged or unwanted cellular components, such as protein aggregates, organelles, or lipids, are then “targeted” for degradation by a protein called p62. Autophagosomes grow and expand, engulfing the selected cargo within their double membranes. Autophagosomes fuse with lysosomes (autolysosomes) and expose the cargo to lysosomal enzymes. The content is finally broken down into its essential components, such as amino acids, fatty acids, and sugars, and the components are recycled and waste products eliminated.
Figure 1: Schematic representation of autophagy and lysosomal steps, and their relationship to neurodegenerative diseases. Reference: Seranova E, Palhegyi AM, Verma S, Dimova S, Lasry R, Naama M, Sun C, Barrett T, Rosenstock TR, Kumar D, Cohen MA, Buganim Y, Sarkar S. Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. J Mol Biol. 2020 Apr 3;432(8):2754-2798. doi: 10.1016/j.jmb.2020.01.024.
Assays to interrogate Lysosomal Function
Currently, there are multiple endeavors aimed at measuring lysosomal quantification, activity, and function. These efforts involve diverse imaging platforms and cells from healthy individuals and those with various neurodegenerative diseases. The assessment includes evaluating changes in several lysosomal markers such as TMEM175, LAMP-1, and LysoTracker™, as well as measuring enzyme activity within the lysosome (Figure 2).
TMEM175 is implicated in various diseases, including Parkinson’s disease.
LAMP-1 is a glycoprotein that plays a crucial role in the structure and function of lysosomes, and it is primarily found on the inner surface of the lysosomal membrane.
LysoTracker™ (fluorescence probe) measures the acidity inside lysosomes and is a marker of both lysosomal content and function.
MagicRed® (fluorescence probe) measures the activity of intracellular enzyme Cathepsin B.
Figure 2:Sygnature in house data. Representative images of control fibroblasts stained with TMEM175, LAMP-1, Lysotracker™ and MagicRed®. Cells were grown overnight in the presence of serum and incubated with antibodies against TMEM175 and LAMP-1, and with the fluorescent probes LysoTracker and MagicRed ®.
Assays to cross-examine Autophagy
Equally, several imaging platforms can be used for monitoring autophagy dysfunction and modulation. Control and diseased cells can be stained using primary antibodies against p62 to investigate autophagic flux, as it ” targets” the proteins and organelles to be degraded (Figure 3), and LC3-I and LC3-II to determine autophagosome formation and maturation. Importantly, levels of p62 and LC3 can be also monitored by Jess-based western blot.
Figure 3: Representative images of control (healthy) and diseased fibroblasts incubated with primary antibody against p62. Cells were grown overnight in the presence or absence of serum. Data was normalized by cell number (per image). AD: Alzheimer`s Disease; PD37: Parkinson`s Disease (donor 1); PD39: Parkinson`s Disease (donor 2).
Conclusion: The Promise of Autophagy and Lysosomal Function
Drugs that modulate autophagy and lysosomal function hold promise as therapeutic targets. However, it is essential to highlight that achieving specificity for autophagy and lysosomal modulation is challenging. Many cellular processes and pathways intersect with autophagy, and drug development must target the intended pathway without causing unintended side effects.
Employing multi-endpoint autophagy and lysosomal function assays may help unravel the underlying biology of neurodegenerative diseases. This could prove invaluable in advancing the most promising new compounds for developing new therapies.